undamentalytics Newsletter

Falberg Kathryn E: insider trades

Chief financial officer, Director at 5 companies we cover. 12 open-market purchases and 9 sales not made under a pre-set plan, reported from September 1, 2010 to March 9, 2026.

Would copying Falberg Kathryn E’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 11 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on September 2, 2010 into $1,627,468 by November 2, 2026, +37.1% a year. The copy held shares only 44% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $38,007, +8.6% a year (the S&P 500 held throughout made $92,007, +14.8% a year). Beta against the index was 0.63. Twelve months after each report, the average purchase was +117.7% against the S&P 500 (median +72.7%), and 91% beat it. Measured from the trade date, the insider’s own timing, the average was +128.4%. After their sales, the shares moved +19.8% against the index over 12 months on average (a negative figure means selling was the right call); 63% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$500k$1.00m$1.50m 201020122014201620182020202220242026 $1.63m$92.0k$38.0k
Copying Falberg Kathryn ES&P 500, same days investedS&P 500, held throughout $10,000 copying Falberg Kathryn E’s open-market purchases from September 2, 2010, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+37.1%
S&P 500, same days invested
+8.6% (held throughout +14.8%)
Time in shares
44%
Sharpe ratio (S&P 500)
0.83 (0.80)
Biggest drop (S&P 500)
−60% (−34%)
Market sensitivity (beta)
0.63
Purchases copied
11

Trade by trade

Falberg Kathryn E: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 11 +20.9% +12.8% 73% 8 1.95 0.091 No reliable evidence
Purchases, 6 months after the report 11 +32.5% +4.6% 64% 8 2.12 0.072 No reliable evidence
Purchases, 12 months after the report 11 +117.7% +72.7% 91% 8 2.48 0.043 Some evidence: ahead
Purchases, 12 months after the trade 11 +128.4% +68.9% 100% 8 2.50 0.041 Some evidence: ahead
Sales, 3 months after the report 9 +5.7% +15.1% 33% 7 0.24 0.82 No reliable evidence
Sales, 12 months after the report 8 +19.8% −3.4% 63% 6 0.74 0.49 No reliable evidence
Sales, 12 months after the trade 8 +25.5% +5.3% 38% 6 0.91 0.40 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Trade Desk, Inc. TTD —38November 16, 2016March 9, 2026
Arcus Biosciences, Inc. RCUS —40June 11, 2019April 2, 2021
Jazz Pharmaceuticals plc JAZZ EVP and CFO21September 1, 2010August 17, 2012
Halozyme Therapeutics, Inc. HALO —20November 14, 2012August 14, 2013
Nuvation Bio Inc. NUVB —10December 5, 2022December 5, 2022

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
March 9, 2026March 5, 2026 TTD Sale $4,655,113 −37.2%not yetnot yet
August 15, 2024August 13, 2024 TTD Sale $14,725,500 +16.7%−64.8%−67.2%
March 12, 2024March 8, 2024 TTD Sale $8,438,201 +16.3%−40.8%−36.8%
December 5, 2022November 30, 2022 NUVB Purchase $483,105 not yetnot yetnot yet
November 23, 2021November 19, 2021 TTD Sale $16,288,481 −14.8%−40.5%−40.6%
April 2, 2021March 31, 2021 RCUS Purchase $567,000 −23.2%−14.7%+1.7%
November 23, 2020November 19, 2020 TTD Sale $16,263,340 −9.8%−5.2%+0.8%
November 13, 2019November 11, 2019 TTD Sale $6,165,550 +25.9%+204.2%+208.9%
June 14, 2019June 13, 2019 RCUS Purchase $110,206 −0.5%+208.5%+218.6%
June 13, 2019June 11, 2019 RCUS Purchase $163,900 +9.2%+246.0%+267.8%
June 11, 2019June 7, 2019 RCUS Purchase $258,799 +7.7%+226.3%+244.7%
March 13, 2019March 11, 2019 TTD Sale $8,218,800 +15.1%−1.6%+9.8%
November 30, 2018November 28, 2018 TTD Sale $2,696,600 +28.0%+50.6%+77.4%
June 16, 2017June 15, 2017 TTD Purchase $961,200 +12.8%+61.0%+68.9%
March 3, 2017March 1, 2017 TTD Purchase $867,600 +28.4%+19.9%+12.4%
November 16, 2016November 14, 2016 TTD Purchase $2,067,800 +26.4%+72.7%+61.2%
August 14, 2013August 12, 2013 HALO Purchase $681,500 +86.2%+22.7%+27.8%
November 14, 2012November 13, 2012 HALO Purchase $260,500 −1.0%+118.7%+128.3%
August 17, 2012August 16, 2012 JAZZ Sale $2,853,570 +11.4%+56.2%+51.5%
November 14, 2011November 11, 2011 JAZZ Purchase $112,080 +16.6%+20.8%+27.9%
September 1, 2010August 30, 2010 JAZZ Purchase $436,224 +67.9%+312.9%+353.0%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Falberg Kathryn E traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.